BioDelivery expects early 2009 approval for buccal fentanyl
This article was originally published in Scrip
BioDelivery Sciences is expecting its buccal film formulation of fentanyl (Onsolis) to receive US approval in the first half of next year for breakthrough pain in opioid-tolerant patients with cancer, after receiving a US FDA complete response letter.
You may also be interested in...
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
Gilead Scienceswill need to conduct another clinical trial of its investigational cystic fibrosis treatment aztreonam lysine for inhalation before the drug can be approved, the US FDAhas said.